ライフサイエンスコーパス: full analysis set

1 based on all randomly assigned patients (the full analysis set).

2 least one dose of study medication (modified full analysis set).

3 disease or treatment-related adverse events (full analysis set).

4 nts receiving at least one osimertinib dose (full analysis set).

5 placebo for 12 weeks (n = 117-125 per group, full analysis set).

6 4%) by ANOVA in an intent-to-treat analysis (full analysis set).

7 ts, and so 299 patients were included in the full analysis set.

8 1069/1095 (97.6%) patients comprised the Full Analysis Set.

9 set) and 149 patients were eligible for the full analysis set.

10 Efficacy analyses were done based on the full analysis set.

11 (n=1319); 2604 (98%) patients comprised the full analysis set.

12 respectively (-2.9% [-8.0% to 1.9%]), in the full analysis set.

13 aseline in HbA1c at week 24 by ANCOVA in the full analysis set.

14 n-inferiority limit of 0.4%) by ANOVA in the full analysis set.

15 s did not meet criteria for inclusion in the full analysis set.

16 s-as-treated population, and efficacy in the full-analysis set.

17 on, and objective response, analysed for the full-analysis set.

18 rd care was assessed in the per protocol and full analysis sets.

19 590 patients were included in the full analysis set (120 in the placebo group, 120 in the

20 In the full analysis set, 327 (74%) patients in the lacosamide

21 Findings were similar in the full-analysis set (673 of 788 children in the aerosol gr

22 100 (40%) of 249 patients in the full analysis set achieved a response, with 19 (8%) achi

23 Responses were assessed in the full analysis set (all patients who received at least on

24 lmost clear" (PGA response), analysed in the full analysis set (all patients who were randomised and

25 Analysis was done on the full-analysis set (all treated patients with measurable

26 nd the time from baseline to first IC in the full analysis set; an independent data review board conf

27 Analysis was by the full analysis set and multiplicity was controlled for wi

28 in ACQ and AQLQ(S) were observed in both the full analysis set and the atopic eosinophilic subgroup.

29 27 patients comprised the full analysis set and were deemed assessable for activit

30 The full analysis set comprised 115 patients receiving cispl

31 The full analysis set comprised 124 placebo- and 117 micafun

32 The full analysis set comprised 1385 patients (692 in the RI

33 The full analysis set comprised 344 patients (172 micafungin

34 Analyses were done on the full analysis set, consisting of all randomised patients

35 h treatment phase, which was assessed in the full analysis set, defined as all randomised patients wh

36 93 patients (3% of the full analysis set) died during the study, of which one d

37 icenter phase 3 trial of intention-to-treat (full analysis set), evaluable (per protocol), and safety

38 2 weeks (SVR12) was assessed in the modified full analysis set (FAS), defined as all patients excludi

39 an intention-to-treat (ITT) population and a full-analysis set (FAS).

40 s were randomly assigned and included in the full analysis set for efficacy analyses (259 vs 259 vs 2

41 risk differences based on the observed data (full analysis set) in the active groups vs the placebo g

42 The full-analysis set included 1081 patients (arm 1: n = 528

43 enicity and safety analyses were done on the full analysis set, including participants who, or whose

44 stigational product and were included in the full analysis set (mean [SD] age, 50 [13] years; 47% fem

45 251 allocated glargine were included in the full analysis set (mean age 58.9 years [SD 9.3], diabete

46 From baseline to 12 weeks in the full-analysis set, mean off-time decreased by 4.04 h (SE

47 We analysed all efficacy endpoints in the full-analysis set (modified intention-to-treat analysis)

48 We assessed efficacy in a full-analysis set of participants with data for baseline

49 worse stomatitis by 8 weeks assessed in the full analysis set (patients who received at least one do

50 se of at least 50% (ACR50) at month 6 in the full analysis set (patients who were randomly assigned t

51 The proportion of patients in the full analysis set predicted by the Kaplan-Meier method t

52 124 (70%) of 177 patients in the modified full analysis set receiving extended-pulsed fidaxomicin

53 ses were by intention to treat (based on the full analysis set); safety analyses included patients ac

54 ho received at least one dose of study drug (full analysis set), SVR12 for the 8-week regimen of graz

55 taking carbamazepine-CR were included in the full analysis set (took at least one dose of study treat

56 ich superiority compared with placebo in the full analysis set was first tested and then, if positive

57 rimary endpoints, assessed at week 24 in the full analysis set, were peak FEV1 response, measured wit

58 in HbA1c after 24 weeks of treatment in the full analysis set, which consisted of all randomly assig

59 lic blood pressure and HbA1c measured in the full analysis set, which included all patients who recei

60 Overall response was analysed in the full analysis set, which was defined as all patients who

61 Analyses were done on the full analysis set with missing values imputed by last ob